Toward Second-Generation Cardiomyogenic and Anti-cardiofibrotic 1,4-Dihydropyridine-Class TGFβ Inhibitors
作者:Daniel Längle、Tessa R. Werner、Fabian Wesseler、Elena Reckzeh、Niklas Schaumann、Lauren Drowley、Magnus Polla、Alleyn T. Plowright、Marc N. Hirt、Thomas Eschenhagen、Dennis Schade
DOI:10.1002/cmdc.201900036
日期:2019.4.17
Innovative therapeutic modalities for pharmacological intervention of transforming growth factor β (TGFβ)-dependent diseases are of great value. b-Annelated 1,4-dihydropyridines (DHPs) might be such a class, as they induce TGFβ receptor type II degradation. However, intrinsic drawbacks are associated with this compound class and were systematically addressed in the presented study. It was possible
药物治疗转化生长因子β(TGFβ)依赖性疾病的创新治疗方式具有重要价值。b-带环的1,4-二氢吡啶(DHP)可能属于此类,因为它们会诱导II型TGFβ受体降解。但是,固有的缺点与此化合物类相关联,并在本研究中系统地解决了。可以在分子的不同部位安装极性官能团和生物立体异构部分,同时保持TGFβ抑制活性。引入2-氨基或7-N-烷基修饰被证明是成功的策略。相对于母体乙基4-(联苯基-4-基)-2,7,7-三甲基-5-氧代-1,4,在pH 7.4时,水溶解度最多可提高7倍,在pH 3时可提高200倍。 ,5,6,7,8-六氢喹啉-3-羧酸盐。